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Abstract: Mitochondria play a central role in a plethora of processes related to the maintenance of
cellular homeostasis and genomic integrity. They contribute to preserving the optimal functioning of
cells and protecting them from potential DNA damage which could result in mutations and disease.
However, perturbations of the system due to senescence or environmental factors induce alterations of
the physiological balance and lead to the impairment of mitochondrial functions. After the description
of the crucial roles of mitochondria for cell survival and activity, the core of this review focuses
on the “mitochondrial switch” which occurs at the onset of neuronal degeneration. We dissect the
pathways related to mitochondrial dysfunctions which are shared among the most frequent or disabling
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s, Amyotrophic Lateral
Sclerosis, and Spinal Muscular Atrophy. Can mitochondrial dysfunctions (affecting their morphology
and activities) represent the early event eliciting the shift towards pathological neurobiological
processes? Can mitochondria represent a common target against neurodegeneration? We also review
here the drugs that target mitochondria in neurodegenerative diseases.
Keywords: mitochondria; cellular homeostasis; neurodegenerative diseases; motor neuron
diseases; neurodegeneration; oxidative stress; mitochondria biogenesis and dynamics; mitochondria
targeting drugs
1. Introduction: The Peculiarity of Mitochondria
Classically, mitochondria were considered the “powerhouse” of the cell, the energetic core
generating ATP for cell activities [1]. Intensive research on their morphology and functions showed
that mitochondria play several different roles.
Interestingly, mitochondria possess their own genome, the mitochondrial DNA (mtDNA), packed
in nucleoids in the mitochondrial matrix in close association with the mitochondrial inner membrane [2].
Mutations at the mtDNA level are causative for many human diseases which are generally defined
as mitochondrial disorders [3]. Moreover, mitochondria are vital and dynamic organelles able to
modify their shape and size in order to respond to the cellular needs and, therefore, to maintain cellular
homeostasis [4]. Mitochondria are the site of the oxidation of metabolites, for example through Krebs’
cycle, and of the β-oxidation of fatty acids [5]. Mitochondria are also the main generators of the reactive
oxygen species (ROS) [6] and they participate to cell proliferation by maintaining a proper redox state
and by recycling oxidized electron carriers. Importantly, mitochondria buffer calcium ions regulate,
in turn, calcium homeostasis [7,8]. This is a crucial mitochondrial function impacting many cellular
pathways such as the neurotransmitters’ release from neurons and glial cells [9].
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In order to maintain the homeostasis of the cell, mitochondria play a crucial role in the choice of
cell fate since they are also able to control cellular programmed cell death [10]. Indeed, mitochondria
can induce apoptosis via caspase-dependent or independent mechanisms, the first by the activation
of pro-apoptotic members of the B-cell lymphoma 2 (Bcl-2) family, the latter by the release of toxic
mitochondrial proteins occurring after mitochondrial loss of function [11].
Mitochondria are extremely sensitive to every subtle change perturbing the homeostasis of the
cell and, in turn, can modify their shape and number. Indeed, the processes of fusion and fission are
fundamental, respectively, to repair a damaged mitochondrion or to increment their number, as in
case of an increased demand of energy or to facilitate their removal when damaged in order to protect
cellular integrity [12].
Additionally, the number and the size of cristae, which are dynamic bioenergetic compartments
of the inner mitochondrial membrane where the respiratory chain occurs, adapt to the needs.
Their plasticity guarantees a constant turnover to assure the balance between regeneration, biogenesis,
and elimination of damaged mitochondria [13]. On the other hand, a regressive event occurring to
mitochondria consists in “mitophagy”, i.e., the process of mitochondria degradation by autophagy [14],
aiming to maintain the correct turnover of mitochondria [15].
Finally, mitochondria are also able to protect cell integrity by preventing the damage induced
by viral infection [16]; indeed, they can also stimulate the innate immune response against these
insults [17].
2. The “Mitochondrial Switch” and Its Impact on Neurodegeneration
Mitochondria are extremely sensitive to the insults that occur and accumulate in the cell,
directly impacting on their function, consequently promoting disease development and progression.
Indeed, besides human hereditary diseases caused by mutations of the mtDNA or in nuclear genes
responsible for mitochondrial deregulation [18], mitochondrial dysfunctions are among the first events
which occur in a vast number of pathological conditions ranking from diabetes [19], inflammatory
diseases (such as multiple sclerosis [20]), to cancer [21] and neurodegenerative diseases [22]. We review
here the “mitochondrial switch” which occurs during neurodegeneration. Neurodegenerative diseases
consist of a group of heterogeneous disorders, but, nevertheless, they are all characterized by the
progressive loss of specific neuronal populations and circuits in the central nervous system (CNS)
triggered by mitochondria dysfunctions [23,24]. Another feature of the majority of neurodegenerative
diseases is the progressive and highly disabling motor decline. Indeed, besides neuronal cells, also
muscle cells are particularly enriched in mitochondria, since they need a high level of energy to
function, and are heavily impacted by mitochondrial dysfunctions. There is growing evidence in
the field exploring mitochondrial defects occurring also in the peripheral nervous system (PNS) and
peripheral cells. Due to the low potential of neural regeneration, mitochondrial damage results in
detrimental effects for neuron survival [25], while in peripheral cells the regeneration capacity is higher
and clinical symptoms are evident only later in the disease.
Globally, in neurodegenerative diseases there is a “switch” in mitochondrial function which
contributes importantly to the transition from a normal physiological to a degenerative condition.
The accumulation of different stresses and the parallel impairment of a number of cell protective
processes elicits neurodegeneration (Figure 1).
During neurodegeneration oxidative stress increases and intracellular ROS are formed, inducing
to mtDNA mutations [1] and also to the disruption of mitochondrial membranes and cristae with a
decrease in ATP production. Among the mechanisms eliciting oxidative stress, it is worth mentioning
the process of deuteronation. Deuterium is a hydrogen isotope, present in nature in a well-defined ratio
with hydrogen (1:6600) [26]: in body fluids, the probability of ATP synthase deuteronation process is
1/15,000 and the increase of this ratio can negatively interfere with ATP synthesis. Moreover, it has
also been demonstrated that deuteronation can enhance formation of free radicals, slowing the
electron trafficking in the mitochondrial electron transport chain (ETC) [27]. This mechanism has been
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evaluated in several conditions or pathologies (i.e., cancer, diabetes, aging, depression) and it can
be reverted replacing heavy water with deuterium depleted water (DDW). Moreover, reduction of
deuterium content by DDW ingestion can rescue long-term memory in Wistar rats restoring altered
deuterium/hydrogen ratio and enhancing synaptic activity [28]. Indeed, DDW is able to promote
antioxidant enzymes’ expression (SOD) and restore glutathione (GSH) levels mitigating, in turn, ROS
formation and preventing fatty acid oxidation [29].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 35 
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DNA (mtDNA) mutations and altered proteins determines the swelling of mitochondria and the 
disruption of their membranes and cristae. Such an altered morphology heavily impacts on function 
determining, among others, decreases ATP production, increased ROS, leading to neuronal death. 
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degenerative process probably starts 20–30 years before the clinical onset and one of the major goals 
of AD research is the early detection before symptom onset to prevent the disease outbreak. Oxidative 
stress-induced damage occurs even before amyloid and tau deposition, and mitochondrial 
dysfunctions are early events which precede neurodegeneration [45]. In AD there is also evidence of 
neuroinflammation; indeed, microglia and reactive astrocytes are closely associated with amyloid 
plaques in patients’ brains [46]. 
Mitochondria appear morphologically and functionally altered, impacting on many processes 
such as excessive ROS formation, and resulting in the decrease of brain energy because of the 
reduction of ATP [47], alteration of calcium homeostasis, and of apoptosis induction [48]: indeed, 
altered levels of apoptotic markers such as Bcl-2, Bax, and caspases have been observed in models of 
AD [49]. Moreover, alterations in mitochondrial dynamics appear early in AD development, 
contributing to impair neuronal autophagy because of defective mitophagy [50]. There is a vast 
literature on the detrimental impact of the accumulation of damage and misfolded proteins inducing 
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Moreover, the accumulation of altered proteins occurring in many neurodegenerative diseases can
determine a decline in mitochondrial biogenesis, impacting on mitochondrial turnover and inducing
structural and functional changes in cells. Different studies showed that various proteins involved
in the above-mentioned processes and in mitophagy are affected in neurodegenerative diseases
determining a dysregulation of these processes [30]. Indeed, mitophagy is required to remove damaged
mitochondria and this process is finely tuned to maintain an equilibrate turnover of mitochondria and,
from a bigger picture, proper cellular development and differentiation. Described for the first time
in 1998 [31], mitophagy has gained considerable interest in the field of neurodegeneration in the last
years; however, because of its fine tuning, it is a difficult target for designing new therapies against
neurodeg neration. Some authors hyp thesized a relation between mitophagy dysregulation and
neurodegenerative diseases, based on the impairment in autophagosome–lysosome fusion and efects
in lysosomal acidification, of en observed in neurodege 32 .
Altogether, these events can trig er the p ocess of mitochond ial membrane permeabilization and,
when severely injured mitochondria are not appropriately removed, they release their contents into the
cytosol and the extracellular environment: this represents a starting point of both apoptosis and necrosis.
This process is called generation of damage-associated molecular patterns (DAMPs) and mitochondria
represent the major site of DAMP formation. By triggering cell death, mitochondria-derived ROS,
calcium, ATP, and the other signaling molecules also lead to neuroinflammation. The process of
neuroinflammation refers to the proliferation and activation of microglia and/or astrocytes (microgliosis,
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astrogliosis) and, to note, neurodegenerative diseases all show evidence of neuroinflammation; the
specific disease-related peculiarities are described later on in the sections dedicated to each pathology.
Interestingly, neuroinflammation is closely related to mitochondria [33]: indeed, mitochondria can
regulate inflammatory signaling and can modulate the innate immunity by generating ROS and, as a
consequence, triggering neurodegeneration [34]. Closely related to ROS and DAMP formation, another
largely studied mechanism by which mitochondria drive neuroinflammation is their ability to activate
the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome [35], in turn leading
to the release of proinflammatory cytokines [36]. Interestingly, NLRP3 localizes in the cytosol and
once activated it translocates into mitochondria and mitochondria-associated membranes (MAMs) [37].
Another mechanism by which mitochondria trigger and sustain neuroinflammation is closely related to
their dynamism: indeed, the inhibition/stimulation of fission induces/reduces NLRP3 inflammasome
assembly and activation, respectively [38].
In particular, mitochondrial dysfunctions (both affecting neuronal survival and triggering
neuroinflammation) have been reported in Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s (HD)
diseases, Amyotrophic Lateral Sclerosis (ALS), and Spinal Muscular Atrophy (SMA), thus representing
a potential biomarker of the diseases, as one major unifying basic mechanism involved in aging and
neurodegeneration [39,40]. In the subparagraphs below we describe the mitochondrial dysfunctions
which are peculiar or shared among the above-mentioned diseases.
2.1. Mitochondrial Dysfunctions in AD
AD is the most common and devastating neurodegenerative disease expected to affect more than
81 million people worldwide by 2040 [41,42]. The first evidence of pathogenic mechanisms in AD has been
the progressive accumulation of beta-amyloid peptide (Aβ) extracellularly in the brain and of neurofibrillary
tangles of hyperphosphorylated tau inside neurons [43], determining the progressive loss of cortical and
hippocampal neurons and inducing brain atrophy, consequent cognitive and memory loss. More recently,
advanced neuroimaging techniques showed evident metabolic alterations in the brain of AD patients at a
very early stage of the disease [44]. Indeed, the degenerative process probably starts 20–30 years before
the clinical onset and one of the major goals of AD research is the early detection before symptom onset
to prevent the disease outbreak. Oxidative stress-induced damage occurs even before amyloid and tau
deposition, and mitochondrial dysfunctions are early events which precede neurodegeneration [45]. In AD
there is also evidence of neuroinflammation; indeed, microglia and reactive astrocytes are closely associated
with amyloid plaques in patients’ brains [46].
Mitochondria appear morphologically and functionally altered, impacting on many processes
such as excessive ROS formation, and resulting in the decrease of brain energy because of the reduction
of ATP [47], alteration of calcium homeostasis, and of apoptosis induction [48]: indeed, altered levels
of apoptotic markers such as Bcl-2, Bax, and caspases have been observed in models of AD [49].
Moreover, alterations in mitochondrial dynamics appear early in AD development, contributing to
impair neuronal autophagy because of defective mitophagy [50]. There is a vast literature on the
detrimental impact of the accumulation of damage and misfolded proteins inducing dysfunctions
at the cellular and mitochondrial level not only in the NS but also in peripheral tissues such as
patients fibroblasts [51] which show mitochondrial calcium dysregulation similar to those occurring
in the brain [52]. Moreover, AD-related proteins, such as the Amyloid Precursor Protein (APP) and
Presenilins (PSs), have been recently described as involved in peripheral processes associated to
muscle trophism, neuromuscular junction (NMJ) formation and mitochondrial morphology [53–55].
Mitochondrial dysfunction in peripheral cells could represent a new target for early and more accessible
diagnosis and, eventually, therapy for AD.
2.2. Mitochondrial Dysfunctions in PD
PD, the second most common neurodegenerative disease in aging, is characterized by the
reduction of dopamine (DA) levels in the striatum due to the degeneration of dopaminergic
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neurons in the SNpc. Patients show a progressive muscle rigidity and tremors due to decrease
in dopaminergic modulation on striatal neurons altering motor systems [56,57]. Inclusions of Lewy
bodies and presence of immunoreactive α-synuclein and ubiquitin are also hallmarks of the disease [58].
Moreover, neuroinflammation plays a role in PD; reactive microglia in the substantia nigra together
with positron emission tomography (PET) imaging studies of PD brains provided early evidence for
the role of neuroinflammation in PD [59,60].
The first evidence of mitochondrial dysfunction in PD came in 1983, when
Langston described chronic parkinsonism effects in young humans after the use of
1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP), which is a prodrug to the neurotoxin
1-methyl-4-phenylpyridinium (MPP+); the latter interferes with the activity of the complex I of
the electron transport chain [61] whose functioning is fundamental for dopaminergic neuron survival.
Decades of research in the field confirmed that mitochondrial dysfunctions are a common feature in
PD and are present in animal models, in induced pluripotent stem cell (iPSCs)-derived neurons and in
patients’ brains [62–65]. Mitochondrial dysfunctions are related to both sporadic and familial PD and are
associated to disturbances of mitochondrial function, morphology, and dynamics (for a detailed review
see Bose and Beal [66]). High levels of ROS, due to the high metabolic demand, determine accumulation
of toxic oxidative species and structural alterations of complex I, affecting mitochondria functionality
in patient brains and mouse models [67,68]. Moreover, α-synuclein oligomers accumulation induces
the permeabilization of the mitochondrial membrane and direct toxicity by increasing ROS production
and consequently leading to neuronal death [69]. Disturbances in calcium homeostasis and calcium
overload could force the opening of the mitochondrial permeabilization transition pore, resulting in
ROS formation, Cyt C release, and apoptosis activation [70].
Mitochondrial dysfunctions in PD are also a result of changes in mitochondria biogenesis
caused by the dysregulation of transcription factors such as the peroxisome proliferator-activated
receptor gamma coactivator 1-alpha (PGC1α), as demonstrated both in mice and humans [71,72].
Furthermore, mitochondrial fragmentation, which occurs rapidly after the loss of membrane potential,
has been observed in PD: indeed, many proteins involved in fusion and fission (such as the
dynamin-related protein 1 (DRP1)) are altered in a model of familial PD [73]. Notably, genes
such as PINK1 and Parkin, which are related to familial-PD forms, are involved in the control of
mitochondrial dynamics [74] and several other genetic mutations, including PINK1, Parkin, DJ-1,
LRRK2, and α-Syn, have been linked to familial PD and the corresponding gene products are also
involved in mitophagy. Additionally, also in PD, mitochondrial dysfunctions are not limited to CNS,
but also involve peripheral tissues as it has been described in skeletal muscles and platelets [62,75].
2.3. Mitochondrial Dysfunctions in HD
HD is an autosomal dominant neurodegenerative disorder, caused by the expansion of CAG repeats
in exon 1 of the huntingtin gene (HTT), leading to the specific loss of GABAergic striatal medium spiny
neurons. Patients show impairments in behavior, muscle coordination, and a progressive mental decline
leading to death [76]. The huntingtin protein (HTT) is involved in many processes such as axonal transport,
signal transduction, and autophagy; its misfolding due to HTT mutation determines the disruption of
the above-mentioned biological processes and of many others [77]. Mitochondrial dysfunctions play a
central role in HD progression. Indeed, abnormal oxidative stress and ROS production, calcium imbalance,
and decreased enzymatic activity of the respiratory chain complexes resulting in the alteration of lactate
production have been observed both in mouse models of HD and in patients’ brains [78–80]. Several studies
have revealed reduced mitophagy in the brain of HD patients [81]. Moreover, accumulation of mtDNA
defects occurs early in HD to the point of being suggested as a potential biomarker of the disease [82,83].
Altogether, these mitochondria-derived defects recall pro-inflammatory activated innate immune cells;
indeed, in HD, a remarkable neuroinflammation has been observed in brains from HD patients and PET
imaging showed that microglia activation correlates with the pathology progression (for an extensive
review on the subject see [84]).
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As for the majority of neurodegenerative disorders, the approach in HD research field has always
been to focus on the neurological symptoms and phenotypes. However, the HTT gene is ubiquitously
expressed [85] and in HD there are important dysfunctions occurring outside the brain. In this regard,
impaired uptake and levels of glucose and cardiac dysfunctions have been shown in HD mouse
models [86,87]. Moreover, HD patients show a high predisposition to diabetes and muscle wasting,
actually before neurodegeneration [88,89]. Interestingly, these dysfunctions are closely connected
to mitochondrial activity and to tissues with high mitochondrial density. Moreover, mitochondrial
alterations are accompanied by oxidative stress in skin fibroblasts of patients [90]; additionally,
the enzymatic activity of the Aco2, which catalyzes the conversion of citrate to isocitrate in the TCA
cycle, is impaired in PBMCs of HD patients and PreHD carriers [91]. Authors suggest it as a potential
biomarker to assess the disease status of both patients and carriers, being an easy and affordable
non-invasive blood test in the clinical routine.
2.4. Mitochondrial Dysfunctions in ALS
ALS is a neurodegenerative disorder due to the loss of upper and lower motor neurons (MNs)
which entails muscle atrophy, progressive weakness, and respiratory failure leading to death [92].
Most cases are sporadic, whereas 10% are familial, with mutations mainly occurring on superoxide
dismutase 1 (SOD1), FUS, TDP43 genes causing the accumulation of the corresponding mutant
proteins [93–95]. However, the etiology of the disease is not yet understood: it includes excitotoxicity,
protein misfolding and aggregation, dysregulation of RNA metabolism, and neuroinflammation [96].
Inflammatory changes have been largely described in ALS patients: astrogliosis is evident within the
spinal cord (both ventral and dorsal horns) and brain (cortical gray matter and subcortical white matter),
whereas microgliosis in the spinal cord ventral horns, corticospinal tract, and motor cortex [97,98].
For sure, mitochondrial-dependent dysfunctions such as ATP deprivation, oxidative stress, impaired
cell signaling together with altered mitochondrial morphology/dynamics are also correlated to the
pathogenesis of ALS and represent very early phenomena [99]. More in details, (i) a high amount of ROS,
free radicals, and other toxic species such as peroxynitrite (ONOO−) [100] and (ii) an alteration of the levels
of expression of proteins involved in mitochondrial fusion and fission (i.e., OPA1, Mitofusin for fusion,
and Fis1 and DRP1 for fission) [100], were observed and (iii) apoptotic signaling is impacted in different
ALS models. The latter triggers cell death, pivotal to keep the organism healthy by eliminating cells
which cannot be rescued from damage, and mitochondria are fundamental for this. Indeed, as previously
introduced, mitochondria induce apoptosis either via caspase-dependent or independent mechanisms.
In ALS, the apoptotic cascade is activated [101] and the mutant SOD1 is playing a major role in this cascade
by interacting with Bcl-2 [102]. Indeed, therapeutic strategies targeting mitochondrial dysfunction to
prevent ALS progression represent a possible treatment option [103].
As for the other neurodegenerative diseases, also in ALS the PNS is dramatically affected and
mitochondrial dysfunctions occur in peripheral tissues as well. MN degeneration is preceded by NMJ
denervation, determining a dying-back retrograde neuropathy. Such defects may cause MN death
by predisposing them to calcium-mediated excitotoxicity, increasing ROS generation and initiating
the apoptotic pathway [104]. Moreover, features of mitophagy in the presynaptic terminals of ALS’
NMJs have been observed [105], suggesting impaired mitophagy as one of the mechanisms causing
degeneration (for a review see Elfawy and Das [106]).
2.5. Mitochondrial Dysfunctions in SMA
SMA affects MNs in children and young adults with a mutation/deletion of the Survival Motor
Neuron 1 (SMN1) gene [107]. SMN has a role in the assembly of small ribonucleoprotein particles, that
function in pre-mRNA splicing and gene transcription and in mRNA transport in MN axons [108].
The outcome of its genetic alteration is a decrease in the levels of the functional protein which results
in motor impairment, muscle atrophy, and premature death [109]. The disease severity in humans
depends on SMN2 which is a highly homologous gene of SMN1. However, SMN2 produces only 10%
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of fully functional SMN; therefore, the degree of compensation relies on patient’s SMN2 copy numbers.
Although the genetic cause of SMA has been identified, many aspects of its pathogenesis remain unclear.
Interestingly, SMN deficiency has been associated to oxidative stress, mitochondrial dysfunction,
and impairment of bioenergetic pathways in different models. SMN silencing in NSC-34 cell lines
induces an increase in cytochrome c oxidase activity and mitochondrial membrane potential, generating
free radicals [110]; in human SMA iPSCs, axonal mitochondrial transport and mitochondrial number
and area are altered [111]. Studies in SMA murine models also show alterations in mitochondrial
respiration, mitochondrial membrane potential and mobility, and confirm an increased oxidative
stress level and fragmentation [112]. Additionally, proteomic studies show that bioenergetic pathways
associated to glycolytic enzymes, such as GAPDH and PGK1, are altered in SMA models [113,114].
Moreover, besides cell-autonomous motoneuronal toxicity, also glial-mediated inflammation seems to
negatively impact on neuronal survival and to promote progression and propagation of the degenerative
process by the activation of apoptotic cascades [115].
Even if SMA has been classically categorized as a MN disease, SMA pathogenesis is more
complex and many mechanisms and districts are involved. Indeed, since SMN protein is ubiquitously
expressed, its lack affects not only MNs, but also NMJs, which show dramatic alterations, including
immaturity, denervation, neurofilament accumulation, and impaired synaptic functions [116].
Additionally, skeletal [117] and heart muscle cells [118] are also dramatically affected: they require
high levels of energy and are, therefore, particularly enriched in mitochondria. Alterations in the
process of mitophagy have been described in the muscles of SMA patients [119]. Some researchers
suggest that these peripheral abnormalities may be the origin of the detrimental effects observed on
MN survival through retrograde signals coming from the muscles/NMJs [120,121]. On the contrary,
others support the idea that peripheral dysfunctions derive from MN degeneration which, in turn,
results in impairment of the nerve-muscle interplay [122]. This ‘chicken or the egg’ question about
where the degeneration starts could help with understanding the important mechanisms of the disease
and the development of disease-modifying interventions which could have greater therapeutic impact
by preferentially targeting the CNS, the PNS, or peripheral tissues. Above all, one possibility is that
mitochondrial impairment, which is an early event in SMA, occurs both at central and peripheral level,
probably representing a relevant target independently from the tissue.
3. Are Mitochondria the Red Thread in Neurodegenerative Diseases?
Considering the enormous economic and social impacts, finding a cure for neurodegenerative
disorders remains a priority in science. Researchers are focused on identifying the common pathogenic
processes shared among these diseases, in order to design new treatments and/or drug combinations
and repurposing. Indeed, scientists and pharmaceutical companies aim at the development of common
therapies for multiple neurodegenerative diseases. To this aim, understanding the co-occurrence and
overall interactions among these diseases is the first step for drug development.
The majority of neurodegenerative disorders have significant genetic components, with genetic
heritability such as for AD, PD, HD, ALS, and SMA. To date, the most common and methodologically
defined approaches used are based on microarrays, next-generation RNA sequencing, statistical and
bioinformatics methods to detect shared genes, single nucleotide polymorphisms (SNPs), and profile
networks of pathways underlying neurodegenerative mechanisms [123–126]. Genome wide association
studies, which represent the largest publicly available resource in the genomic domain, reveal the
similarities among diseases and can help in the process of drug screening and discovery (for a
comprehensive review see Arneson et al. [127]). In addition to genetics, considering that the majority
of the forms of neurodegeneration are sporadic, factors such as the ageing of the global population,
the lifestyle, and the exposure to chemicals are taken into account too and are nowadays known risk
factors for neurodegeneration [128,129].
Neurodegeneration can be defined as a process characterized by the loss of neuronal populations,
progressive cognitive decline, and/or motor symptoms. As largely described above, there is
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overwhelming evidence of impaired mitochondrial functions as a causative factor driving the
development of neurodegenerative diseases together with the unavoidable elevation of oxidative
stress, the increase of free radicals in the brain, impaired DNA repair capability, and decreased tissue
regeneration. Indeed, besides the intrinsic differences among diseases, mitochondria are a shared
key crossing point in the biological processes driving neurodegeneration and determining the clinical
outcomes. Mitochondrial dysfunctions could be considered a possible red thread in neurodegenerative
diseases. This is the consequence of the fact that mitochondria, besides being the powerhouse of
eukaryotic cells, are fundamental organelles involved in critical pathways connected to cell growth
and differentiation, cellular signaling, apoptosis, and cell cycle control. Together with the fact that
mitochondrial dysfunctions appear at the early disease onset and contribute to disease progression,
they are a hallmark of neurodegeneration.
Interestingly, the mitochondrial switch driving neurodegeneration occurs indistinctly in every tissue,
even in the periphery although neurodegeneration has always been approached and studied focusing on the
CNS. To some extent, one could investigate neurodegenerative disorders as affecting mitochondria primarily.
In Figure 2 the mitochondrial dysfunctions and effects on the CNS, PNS, and periphery are represented for
AD, PD, HD, ALS, and SMA. Therefore, targeting mitochondria can represent new therapeutic approaches
for different neurodegenerative diseases. Below, molecules tested for neurodegeneration targeting the
main pathways related to mitochondrial-dependent dysfunctions, such as oxidative stress, mitochondrial
biogenesis, mitochondrial membrane permeability and dynamics, are listed.
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Figure 2. The process of neurodegeneration in t s system (CNS), in the periphery and
across diseases. Neurodeg n ration is a progressive process taking place not only in the C S b t als in
the periph y. After the accumulation of damage t the cellular and, i particular, mitoch ndrial level,
the switc from physiolog t path logy is fast and r rely ve sible and it is occurring in many cell
types. Indeed, it occurs in the CNS but also in the periphery, in particular the neuromuscular junction
(NMJ), the skeletal muscles, blood cells, and fibroblasts. Moreover, the major pathways involved are
linked to ROS and free radical formation, alterations in ATP formation, calcium homeostasis, apoptosis,
mitochondrial turnover and dynamics, and neuroinflammation in terms of microglia and astrocytes
activation. These pathways are affected in all the neurodegenerative diseases discussed in this review.
Increase of ROS is represented by the black arrow pointing up and reduction in energy production by
the black arrow pointing down. Created with BioRender software.
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4. Therapies Targeting Mitochondria
Despite different time of onset, symptoms, and etiology, the above-mentioned neurodegenerative
pathologies share the progressive neuronal degeneration [130,131], resulting in the loss of neuronal
populations and impairment of neurotransmission (a highly energy-demanding process) [132].
However, even if these neurodegenerative diseases have been studied for decades, up to now,
most of them lack of disease-modifying therapies: the available treatments (summarized together with
their main effects and limitations in Table 1) are generally symptomatic and they are unable to fully
prevent the disease progression [133–138].
Nevertheless, in the last years the landscape of the potential drugs has expanded, in the attempt
not only to stop the disease progression, but also to prevent the onset of symptoms [139]. To this aim,
the identification of an early and possibly common target could represent a turning point in the treatment
of these pathologies: in this scenario, mitochondria could be considered promising targets, because (i) their
impairment can be detected since the earliest stages, influencing the onset and progression of the diseases,
(ii) their dysfunctions are common to all the pathologies described here [140,141]. In the next paragraphs
we will focus on the most common therapies that target these organelles in neurodegenerative diseases
and that have been object of preclinical studies and/or whose role has provided promising outcomes in
clinical trials, classifying them according to the mechanisms of action.
Table 1. Available treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease (HD), Amyotrophic Lateral Sclerosis (ALS), and Spinal Muscular Atrophy (SMA).
The table summarizes the most common therapies for these neurodegenerative pathologies.
Unfortunately, the majority of these treatments are only symptomatic or palliative and cannot stop the
disease progression (especially for AD, PD, HD, and ALS) or are less effective in milder and late treated
patients (as in the case of SMA).
Pathology Drug Mechanism ofAction Main Effects Main Limitations References
AD
Donepezil,
Galantamine,
and Rivastigmine
Cholinesterase
inhibitors
Acetylcholine increase
at synaptic level
Low CNS selectivity;
high doses cause
gastrointestinal
toxicity
[135,142–144]
Memantine
Noncompetitive
NMDA
antagonist
Reduction of neuronal
dysfunctions due to
glutamate
downregulation
Low beneficial effects
in clinical trials
(maybe due to late
administration)
PD
Levodopa +
Carbidopa/Levodopa
+ Benserazide
DA precursor +
DOPA
decarboxylase
inhibitor
SNC DA level increase
Ineffective in
mitigating some
motor and
non-motor
symptoms;
dyskinesia
[138,145,146]
Levodopa +
Carbidopa +
Entacapone
DA precursor +
DOPA
decarboxylase
inhibitor +
COMT inhibitor
SNC DA level increase Motor fluctuations;dyskinesia
Pramipexole and
Apomorphine DA agonists
Activation of DA
receptors
Less effective than
Levodopa;
dyskinesia;
expensive
Selegiline, Rasagiline,
and Safinamide
MAO-B
inhibitors
Prevention of DA
metabolism
Mild efficacy in
monotherapy
Amantadine Antiviral drug
Bradykinesia, tremor
and rigidity mitigation,
and Levodopa-induced
dyskinesia reduction
Several side effects
such as hallucination,
confusion, blurred
vision, and edema
Trihexyphenidyl Anticholinergic Tremor reduction Mild effects on motorsymptoms
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Table 1. Cont.
Pathology Drug Mechanism ofAction Main Effects Main Limitations References
HD
Tetrabenazine
(XENAZINETM) and
Deutetrabenazine
(AUSTEDOTM)
Vesicular
monoamine
transporter
(VMAT) type
2 inhibitor
Treatment of
pathology- associated
chorea (synaptic DA
reduction)
Only symptomatic
treatment [134]
ALS
Riluzole
Glutamatergic
transmission
blocker
Antiexcitotoxic effects
Effectiveness limited
to the first six
months of therapy
[137,147]
Edaravone
(RADICAVATM) Antioxidant
Free radical scavenger
(neuroprotection)
Prescription only for
limited cohort of
patients
SMA
Nusinersen
(SPINRAZATM)
ASO acting on
SMN2
pre-mRNA
splicing
Increase of full-length
SMN production
Limited efficacy in
milder or late-treated
patients; expensive;
repetitive intrathecal
injections
[133,136,148]
Onasemnogene
Abeparvovec
(ZOLGENSMATM)
Smn1 delivering
by the
adeno-associated
virus AAV9 (only
FDA approved,
not yet in
therapy)
Increase of full-length
SMN production
Limited efficacy in
milder or late-treated
patients; expensive
AAV=adeno-associated virus; ASO=antisense oligonucleotide; COMT= catechol-O-methyltransferase; DA = dopamine;
FDA = Food and Drug Administration; MAO = monoamine oxidase; NMDA = N-methyl-D-aspartate; VMAT = vesicular
monoamine transporter.
4.1. Antioxidant
As previously mentioned, ROS are produced by mitochondria both in physiological and pathological
conditions [149] and can be responsible for onset and progression of many neurodegenerative
diseases [150,151]. Furthermore, as discussed above, one of the major events related to neurodegenerative
diseases, driven by the redox status, is microglial activation-derived neuroinflammation [152]: the induction
of the expression of proinflammatory genes leading to the release of cytokines and chemokines can represent
a consequence of the uncontrolled ROS production by mitochondria. This chronic inflammatory state is
characteristic of many neurodegenerative diseases [153].
Many synthetic or natural molecules (summarized in Table 2) have been investigated, since they
can reduce the ROS-induced effects, among which neuroinflammation, in a similar way due to their
molecular structure, through direct or indirect mechanisms.
4.1.1. Synthetic Antioxidants
As reviewed by Cenini and Voos [139], some compounds such as MitoQ play a key role in
the ETC preventing ROS formation due to the electron leakage to oxygen. It has a lipophilic tail
that lets it cross the inner mitochondrial membrane (IMM) and a benzoquinone ring that can be
reduced to ubiquinol and oxidized back to ubiquinone, performing the antioxidant activity [154,155].
It induced neuroprotective effects in preclinical studies in vitro on AD cortical neurons and determined
an increased lifespan and a milder cognitive decline, due to cholinergic neurons protection and
synaptic preservation in AD mice [139,155]; furthermore, MitoQ prevented PD mice dopaminergic cells
loss [156,157], increased lifespan and hindlimb strength of SOD1G93A mice [158], and finally mitigated
muscle wasting in R6/2 HD mice [159].
As reviewed by Weissig [160], SkQ1 belongs to the quinone derivative group and it is still analyzed
only in preclinical studies in OXYS rats providing learning and memory enhancing and behavioral
improvement [139,161]. SkQ1 and MitoQ share the TPP+, a lipophilic cation that facilitates molecules
targeting to mitochondria; the same residue is also present in Mito-Apo, another compound that
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displayed its neuroprotective effects in AD and PD both in vitro and in vivo providing, respectively,
a reduction of neuronal degeneration [162] and an attenuation of motor deficit in PD mouse models
when bound to apocynin, a NADPH oxidase inhibitor that counteracts ROS formation [158,163,164].
Beyond quinone structures, there are many other aromatic molecules that can provide themselves
not only redox activity but also lipophilic properties to cross the membrane. For instance,
the phenothiazine ring allows Methylene Blue both to reach the mitochondrial matrix and to perform
redox reactions reducing ROS formation [165,166]; indeed, this activity is ensured in vivo, increasing
attentional functions and preserving dopaminergic neurons in a PD rat model [157,167]. In Szeto-Schiller
tetrapeptides the tyrosine or dimethyl tyrosine residues can scavenge ROS but, differently from the
previous drugs, they act in the IMM without joining the mitochondrial matrix, as described by Rocha
et al. [168]; both in in vitro and in vivo studies they have shown multiple functions deriving from
the antioxidant activity, making it a promising compound for AD therapy [139], but they have also
provided interesting results in further studies on ALS cell models and in PD and ALS mice, ensuring
increased survival and motor performance enhancement due to neuroprotective effects [169].
Not only an aromatic structure can perform antioxidant activity scavenging ROS: thanks to its
dithiolane ring, α-Lipoic acid [170] can perform redox reactions promoting a reduction of cytotoxic
events in vitro and an amelioration of cognitive functions in AD animal models; the first promising
results on AD patients have been already obtained in association with other antioxidant compounds
but, unfortunately, there are no clinical trials to evaluate efficacy of isolated α-Lipoic acid [171].
Unlike the aforementioned compounds, inosine plays an indirect antioxidant activity: its derivative,
urate, exerts neuroprotective effects mediated by the nuclear factor erythroid 2-related factor 2 (Nrf2),
one of the main controllers of the response to oxidative stress; moreover, it seems to be able to increase
GSH levels and its release. This was highlighted in different experimental studies in vitro but positive
outcomes have also emerged in PD mouse models, encouraging scientists to consider preclinical
studies also on ALS models [172,173]. Nowadays, there are some clinical trials that have confirmed
safety and efficacy of inosine in increasing urate levels in both pathologies (NCT00833690; [174];
NCT02288091; [175]).
Finally, as reviewed by Reiter et al. [176], melatonin is able to counteract oxidative stress not
only directly interacting with free radicals [177], but also by stimulating antioxidant enzymes and
upregulating GSH synthesis, through an indirect pathway. For these reasons, its use in the treatment
of neurodegenerative diseases has been proposed: in vitro it exerted an antiapoptotic activity and
in vivo it improved behavioral and cognitive functions and extended the lifespan of AD and ALS mice
and rats [151,178–181]; furthermore, it enhanced locomotor performances in PD mouse models [182].
Otherwise, meta-analysis and clinical trials on AD and PD patients revealed only an improvement in
sleep quality without any ameliorations in terms of cognitive or motor functions and clinical trials
testing melatonin in a specific range dose to establish its neuroprotective activity are needed [181–183].
Similarly, N-Acetylcysteine (NAC) can exert both a direct and an indirect antioxidant effect, reacting
with ROS or restoring GSH levels [184–186]. Its efficacy has been already evaluated in vitro and
in vivo, where it, respectively, downregulated apoptotic markers in AD and PD cells and enhanced
mitochondrial activity (for example increasing brain connections or reducing lipid peroxidation [186])
and preventing the degeneration of MNs derived from SMA iPSCs [118]; furthermore, a mitigation
of cognitive and motor impairment has been observed on HD mice [187]. Finally, different clinical
trials have examined its efficacy on AD patients showing an amelioration in cognitive and behavioral
functions (NCT01320527; [188]) and an increase in GSH brain levels in PD patients, although this
outcome has not been obtained in all clinical trials, maybe because of NAC low oral bioavailability [186].
4.1.2. Natural Antioxidants
Beside the synthetic antioxidants, several natural compounds (taken as dietary supplements) can
play a direct antioxidant role. Among them, Vitamin C can scavenge free radicals when oxidized to
dehydroascorbate and recycled back to ascorbic acid through a radical mechanism [189]; its effectiveness
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in reducing apoptotic process and in regulating ROS balance and oxygen consumption has been already
proven, respectively, on Aβ1-42 peptide-treated human cortical neurons and in APP/PSEN1 and
5XFAD Tg mice [190–192]. Even Vitamin E, that includes its tocopherol and tocotrienol derivatives,
can regenerate tocopherol structure after lipid peroxidation inhibition, in a mechanism that can involve
Vitamin C or GSH, as described by Stahl and Sies [189]. Preclinical studies on aged mice and on
APP/PS1 mice showed promising results; indeed, ROS scavenging can recover mitochondrial damage,
but also enhance mitochondrial biogenesis and bioenergetics: this in turn has effects on cognitive and
behavioral impairment improvement [193–195]. Despite these encouraging outcomes in preclinical
stages, further clinical trials are needed to investigate the real effects of Vitamin E supplementation in
AD in order to consider all the factors that can influence patients’ responsiveness [196]. Even in ALS,
Vitamin E intake is debated because the positive outcomes obtained in preclinical trials on ALS onset
and progression cannot always be translated to patients [151,197].
Carotenoids (i.e., Astaxanthin) can exert a double antioxidant activity, since they can both quench
ROS through a radical mechanism (for an extended review see Fiedor and Burda [198]), or improve the
activity of several antioxidant enzymes like SOD, CAT, and GPX [199]; for instance, their efficacy has
been already proven on an AD cell model showing a prevention of synaptotoxic events due to ROS
production [200].
Table 2. Antioxidant compounds for neurodegenerative disease treatment. The table lists synthetic
and natural antioxidant compounds tested for the treatment of neurodegenerative diseases both in
preclinical and clinical studies. The most recent and promising studies are collected here. For clinical
trial ID we referred to https://clinicaltrials.gov.
Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies / PMCID Preclinical Results
Clinical Trials /
Trial ID Clinical Results
Synthetic
antioxidant
α-Lipoic
acid
AD
Preclinical in vitro
and in vivo
PMC6914903 [171]
In vitro studies:
mitigation of cytotoxic
effects (reduction of
ROS production and
lipid peroxidation).
Clinical trials
information is
collected here
PMC6914903
[171]
Safety and neuroprotection are
confirmed in combination with other
antioxidants conventional treatments but
further studies on interactions between
them are needed. Isolated α-lipoic acid
activity has to be tested
In vivo studies:
memory and learning
improvement
Inosine ALS Under evaluation
Clinical trial
Phase
1 Completed,
PMC6292193
[175]
NCT02288091
Safety, tolerability, and efficacy in
increasing urate serum levels
Inosine/Urate PD
Preclinical in vitro
and in vivo
PMC5233635 [173]
In vitro:
neuroprotection
(Nrf2 transcription
and nuclear
translocation; GSH
increasing)
Clinical trial
Phase
2 Completed,
PMC3940333
[174]
NCT00833690
Safety, tolerability, and effectiveness in
increasing urate serum levels
In vivo: behavioral
improvement;
reduction of
dopaminergic
neurons loss
Melatonin AD
Preclinical in vitro
and in vivo
PMC6826722 [181]
In vitro: protection
from apoptosis and
neuroinflammation.
Meta-analysis of
controlled trials
information is
collected in the
following work
PMC6826722
[181]
Improvement in sleep quality but no
ameliorations in cognitive functions
when melatonin is administered not in
combinations with other AD treatments
In vivo: improvement
in cognitive functions
and behavioral
activities (reduction of
neuronal death and
beneficial effects on
synapses), protection
against
neuroinflammation
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Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies / PMCID Preclinical Results
Clinical Trials /
Trial ID Clinical Results
Melatonin ALS
Preclinical in vitro
and in vivo
PMC7016185 [151]
In vitro: apoptosis
inhibition
Clinical safety
trial information
is collected in
the following
work PMID:
22739839 [183]
Safety, improvement of sleep quality,
and reduction of oxidative stress
biomarkers. Further studies to confirm
its efficacy alone or combined to other
drugs different from Riluzole are needed
In vivo: survival
extension and delay
in disease progression
(oxidative damage
reduction and
protection against
neuroinflammation)
Melatonin PD Preclinical in vivoPMC6646522 [182]
Reduction of
locomotor deficit
(downregulation of
lipid peroxidation and
dopaminergic cells
loss) and of
neuroinflammation
Clinical trials
information is
collected in the
following work
PMC6646522
[182]
Improvement in sleep quality but no
benefits on motor activity
Methylene
Blue PD
Preclinical in vivo
PMID: 30219247
[157]
Attentional functions
and motor
improvement and
neuroprotection
Mito-Apo AD Preclinical in vitroPMC5392427 [162]
Mito-Apo on
dopaminergic
neuronal cell line,
mouse primary
cortical neurons,
and a human
mesencephalic cell
line: reduction of
neuronal
degeneration and of
neuroinflammation
Mito-Apo PD
Preclinical in vitro
and in vivo
PMC4995106 [163]
PMC5651937 [164]
In vitro:
neuroprotection
against oxidative
stress
In vivo: motor deficit
and
neuroinflammation
attenuation
(neuroprotection)
MitoQ AD
Preclinical in vitro
and in vivo
PMC6716473 [139]
In vitro:
neuroprotection
against oxidative
stress and neurites
outgrowth
In vivo: mitigation of
cognitive decline and
elongation of lifespan
MitoQ ALS
Preclinical in vivo
PMID: 24582549
[158]
MitoQ increases
hindlimb strength and
promotes lifespan
elongation of
SOD1G93A mice
MitoQ HD Preclinical in vivoPMC6970224 [159]
MitoQ on R6/2 HD
mouse model:
reduction of
ROS-induced
autophagy
MitoQ PD
Preclinical in vivo
PMID: 29842922
[156]
MitoQ prevents
dopaminergic
neurons loss in a
6-OHDA PD mouse
model promoting
mitochondrial fusion
N-Acetylcysteine AD
Preclinical in vitro
and in vivo
PMC6320789 [186]
In vitro: apoptosis
inhibition and
protection against
neuroinflammation
Clinical Trial
Phase
2 Completed
PMID: 25589719
[184]
NCT01320527
Cognitive and behavioral improvement
In vivo: increase of
brain connections,
GSH levels, TH and
Complex 1 activity
and protection against
neuroinflammation
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Table 2. Cont.
Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies / PMCID Preclinical Results
Clinical Trials /
Trial ID Clinical Results
N-Acetylcysteine HD Preclinical in vivoPMC3967529 [187]
Cognitive and motor
deficits improvement
N-Acetylcysteine PD
Preclinical in vitro
and in vivo,
PMC6320789 [186]
In vitro: apoptosis
inhibition
Clinical trials
information is
collected in the
following work
PMC6320789
[186]
Increase of GSH brain levels
In vivo: increase of
GSH levels and
reduction of lipid
peroxidation
N-Acetylcysteine SMA Preclinical in vitroPMC4728333 [119]
NAC on iPSCs:
mitigation of motor
neuron degeneration
(increasing in
mitochondrial
number and axonal
transport, reduction
of axonal swelling,
and apoptosis
inhibition)
SkQ1 AD Preclinical in vivoPMC6716473 [139]
Cognitive and
behavioral
improvement
(reduction of ROS
formation,
improvement of
mitochondrial
biogenesis and
bioenergetics and
mitochondrial
structure protection)
Szeto-Schiller
tetrapeptides AD
Preclinical in vitro
and in vivo
PMC6716473 [139]
In vitro:
mitochondrial
biogenesis,
bioenergetics and
dynamics
improvement,
and apoptosis
inhibition
In vivo: anterograde
axonal transport and
synaptic activity
enhancement
Szeto-Schiller
tetrapeptides ALS
Preclinical in vitro
and in vivo
PMC4267688 [169]
In vitro: mutant cells
apoptosis inhibition
In vivo: increase of
survival and
behavioral
improvement in
SOD1G93A mice
(neuroprotection)
Szeto-Schiller
tetrapeptides PD
Preclinical in vivo
PMC4267688 [169]
Lifespan extension
and motor
performances
improvement
(neuroprotection)
Int. J. Mol. Sci. 2020, 21, 3719 15 of 35
Table 2. Cont.
Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies / PMCID Preclinical Results
Clinical Trials /
Trial ID Clinical Results
Natural
antioxidant
Carotenoids
(Astaxanthin) AD
Preclinical in vitro
PMC4791503 [200]
Astaxanthin on
Aβ1-42 oligomers-treated
hippocampal neurons:
protection against
ROS production
reducing synaptotoxic
events and
neuroinflammation
Vitamin C AD
Preclinical in vitro,
PMID: 12592670
[190], and in vivo
PMC5623070 [192]
PMC3944243 [191]
In vitro: inhibition of
apoptosis due to
mitochondrial
membrane
depolarization and
DNA fragmentation
In vivo: Preservation
of mitochondrial
morphology
(attenuation of
oxidative stress
damage) and
apoptosis inhibition
Vitamin E AD
Preclinical in vitro,
PMC4333972 [193]
and in vivo
PMC4537756 [194]
and PMID:
29656360 [195]
Vit.E on astrocytes
treated with
glutamate:
mitochondrial injuries
recovering (MMP
stabilization and lipid
peroxidation
reduction)
Epidemiological
studies
information is
collected in the
following work
PMC6645610
[196]
Results insufficient. Additional studies
on AD patients are needed
Vit.E in aged mice:
increase of TFAM,
MMP, and ATP levels
Vit.E on
APP/PS1 mice:
cognitive and
behavioral
performances
improvement (Aß
accumulation
prevention, oxidative
stress reduction)
Vitamin E ALS
Preclinical in vivo
PMID: 8967745
[197]
Vit.E determines ALS
delay onset and slows
its progression
Clinical trials
information is
collected in the
following work
PMC7016185
[151]
Several clinical studies have shown
conflicting outcomes in slowing ALS
onset and progression, but further
studies are needed
Mito-Apo = Mito-Apocynin; NAC = N-Acetylcysteine; OHDA = hydroxydopamine; SS = Szeto-Schiller;
TH = Thyrosine hydroxylase; Vit. = Vitamin.
4.2. Mitochondrial Biogenesis and Permeability
Mitochondrial biogenesis is an important process, since increasing mitochondria number can
partially rescue, at least from a quantitative point of view, the low efficiency of the impaired ones,
through a compensatory mechanism [201]. In this scenario, PGC-1α represents the main regulator
in mitochondrial biogenesis (Table 3). Its reduction has been related to PD onset, because it could
indirectly induce alpha-synuclein oligomerization: in fact, it has been proven that PGC-1α restoration
can reduce alpha-synuclein toxicity both in cell culture and in transgenic animals [202]. To further
maintain mitochondrial functionality, the prevention of the formation of the mitochondrial permeability
transition pore (mPTP) could be a good strategy: it can avoid mitochondria swelling, outer membrane
disruption, and releasing of apoptotic factors [203], finally resulting in neuronal death. According to
this, Olesoxime is a molecule that can bind two proteins of the outer mitochondrial membrane
(TSPO and VDAC), in this way preventing the mPTP opening [204]. Following different preclinical
investigations in which it provided lifespan prolongation in transgenic mouse models [204], this drug
has been considered a promising compound for ALS and SMA patients but, even if clinical trials on
ALS have failed [205], a Phase 2 trial on SMA patients has shown an amelioration in motor functions
(NCT01302600) that encouraged further investigations [206]. Moreover, some studies on PD and HD
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models have confirmed both in vitro and in vivo its key role in mitochondria stability resulting in a
mitigation of cognitive and behavioral impairment [206].
Table 3. Compounds acting on mitochondrial biogenesis and permeability. The table shows the
promising experimental results obtained in vitro and/or in vivo after the administration of PGC-1α (to
enhance mitochondria biogenesis) and Olesoxime (to regulate mitochondria permeability). The latter
one already gave promising results in SMA patients. For clinical trial ID we referred to https:
//clinicaltrials.gov.
Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies /
PMCID
Preclinical Results
Clinical
Trials / Trial
ID
Clinical Results
Mitochondrial
biogenesis PGC-1α PD
Preclinical
in vitro and
in vivo
PMC4293280
[202]
PGC-1α restoration in a
cell culture model for
α-synuclein
oligomerization
In A30P α-syn
transgenic animals:
α-synuclein
oligomerization
reduction
Mitochondrial
permeability
Olesoxime HD
Preclinical
in vitro and
in vivo
PMID:
31283931
[206]
Mitochondrial
membrane stabilization;
cognitive and
behavioral
improvement
Olesoxime PD
Preclinical
in vitro and
in vivo
PMID:
31283931
[206]
Mitochondrial activity
enhancement and
apoptosis inhibition
Olesoxime SMA
Preclinical
in vivo
PMC4033913
[204]
Lifespan elongation
Clinical trial
Phase
2 Completed
PMID:
31283931
[206]
NCT01302600
Efficacy in motor
improvement and
safety have been
confirmed
It could be
administered in
combinatorial
therapy
4.3. Mitochondrial Bioenergetics
Neurotransmission and metabolism require high energy levels, and mitochondria are the key
organelles for ATP production; therefore, acting on impaired mitochondria with compounds that may
support neurons in carrying on their activity could be a good strategy in neurodegenerative diseases
treatment (Table 4).
As exhaustively explained by Carrera-Juliá et al. [151], NAD+ is a compound involved in many
metabolic pathways that are related to neuroprotection and, in turn, its intake could be considered a
promising approach to treatment of neurodegenerative diseases. Indeed, acting in glycolysis, Krebs
cycle, and oxidative phosphorylation, it can contribute to preserve cognitive functions, representing a
promising compound for AD treatment [139,207]. Furthermore, the role of Nicotinamide Riboside,
a NAD+ precursor, has been investigated in vivo in AD models and in vitro in PD and ALS mutated
cells, providing a wide range of positive outcomes, from mitochondrial biogenesis enhancement to
ROS production inhibition, reflected in cognitive improvement due to an increase of synaptic plasticity
for what concerns AD mice [64,151,208].
Similarly, triheptanoin can provide several metabolites that powers Krebs cycle, both in CNS and
in peripheral tissues [209]. Therefore, its anaplerotic role has been investigated at early stages of HD:
however, until now, only one clinical study has confirmed such efficacy, showing an improvement
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in patients’ brain metabolic profiles (NCT01882062; [210]). Furthermore, thanks to its function,
triheptanoin significantly delayed motor neuron loss and motor symptom onset in SOD1G93A mice [211]:
for this reason, it has been also considered as a promising treatment to slow ALS progression.
Table 4. Compounds acting on mitochondrial bioenergetics. The table lists compounds involved in
mitochondrial bioenergetics enhancement, providing an overview of preclinical and clinical studies.
For clinical trial ID we referred to https://clinicaltrials.gov.
Therapeutic
Function
Drug /
Molecule Pathology
Preclinical
Studies /
PMCID
Preclinical Results Clinical Trials /Trial ID
Clinical
Results
Mitochondrial
bioenergetics
NAD AD
Preclinical
in vitro and
in vivo
PMC6716473
[139]
Mitochondrial
bioenergetics and
dynamics enhancement
and mitophagy
stimulation; cognitive
functions improvement
Clinical trial
information is
collected in the
following work
PMID:15134388
[207]
Lower
cognitive
impairment
than patients
treated with
placebo
Nicotinamide
Riboside AD
Preclinical
in vivo
PMC7016185
[151]
Learning and memory
improvement (synaptic
plasticity amelioration,
neurogenesis
enhancement,
and apoptosis
reduction)
Nicotinamide
Riboside ALS
Preclinical
in vitro
PMC4865928
[208]
Protection against
oxidative stress
Nicotinamide
Riboside PD
Preclinical
in vitro PMID:
29874584 [64]
Mitochondrial
biogenesis and
bioenergetics
enhancement; MMP
reduction;
downregulation of ROS
formation
Triheptanoin ALS
Preclinical
in vivo
PMC5001695
[211]
Motor symptoms onset
delay in SOD1G93A mice
thanks to mitigation of
motor neuron loss
Triheptanoin HD Not found
Clinical trial
Phase
2 completed
PMC4336068
[210]
NCT0188206
Brain
metabolic
profile
enhancement
NAD = nicotinamide adenine dinucleotide.
4.4. Compounds Targeting Multiple Mitochondrial Dysfunctions
Besides all the compounds listed until now, there are several other molecules which may act at the
same time on many pathways linked to mitochondrial dysfunctions (for a general overview see Table 5).
For example, phenylpropanoids are natural molecules derived from the amino acid l-phenylalanine;
among them, resveratrol, curcumin, and flavonoids (including epigallocatechin-gallate, quercetin and
wogonin) can (i) regulate mitochondrial biogenesis, enhancing the expression of several activators
(i.e., PGC-1α, SIRT1, Nrf1, Nrf2, and TFAM), (ii) improve mitochondrial bioenergetics, (iii) enhance ATP
production, and (iv) counteract apoptotic pathways (as described in Kolaj et al. [212]). Furthermore, they
are able to prevent oxidative stress (i) quenching free radicals through a direct mechanism [213],
(ii) upregulating the expression of antioxidative enzymes via the activation of different signaling
pathways (i.e., Nrf2), even increasing GSH production [214,215], and (iii) inhibiting ROS-forming
enzymes like XO and NOX [216]. Therefore, all these compounds have been investigated as potential
therapeutics to treat mitochondrial dysfunctions characterizing many neurodegenerative diseases.
When administered in vitro in AD and ALS cell lines, these compounds can significantly increase
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cell survival, reducing oxidative stress and restoring MMP [139,151,217–219]; likewise, preclinical
studies in vivo on AD and ALS models confirmed their neuroprotective effects, improving cognitive
functions and delaying motor symptom onset and disease progression, respectively [73,139,151,220].
Furthermore, the first promising results on human clinical trials have appeared: in fact, curcumin
was effective in lifespan elongation and in decreasing disease progression in ALS patients, although
the low oral bioavailability makes new delivery methods necessary [151]; and resveratrol has shown
to be safe, tolerable, and effective in mitigating cognitive decline in clinical trials on AD patients
(NCT01504854 [221]; NCT00678431 [222]).
Other compounds, derived from drug repurposing studies, are extremely effective in mitigating
mitochondrial alterations, although initially employed for different therapeutic purposes and acting on
different pathways. Among them, pramipexole, a dopamine receptor agonist approved for PD therapy,
seems to have an antioxidant role independent from dopaminergic receptors activation [223]: indeed,
it plays a key role in neuroprotection, preventing ROS formation and consequently reducing cell
death, as proven on SH-SY5Y cells exposed to MPP+ [157,224]. Moreover, as demonstrated through a
patch-clamp experiment on rat liver and brain mitochondria, pramipexole may also inhibit the mPTP
opening, preventing mitochondria Ca2+-dependent swelling [225].
Another compound investigated for PD treatment is the Selegiline-analog
N-Methyl,N-propynyl-2-phenylethylamine, a MAO-B inhibitor. Besides ameliorating motor
impairments of MPTP-treated mice, it was also able to (i) increase complex I activity and
UCP-2 expression (reducing oxidative stress) and (ii) to inhibit p53 mitochondrial translocation
(maintaining mitochondrial membrane integrity and counteracting apoptosis) [226].
Other molecules, which are not specific for the treatment of neurodegenerative diseases,
can counteract mitochondrial alterations, preventing a wide range of altered mechanisms. For instance,
3-N-butylphthalide (NBP), a compound widely employed in the treatment of ischemic stroke in China
thanks to its ability in restoring microcirculation [227], can (i) maintain mitochondria permeability and
dynamics (preventing mitochondria swelling), (ii) improve mitochondria bioenergetics (increasing
complex IV activity), (iii) prevent cytochrome c release and caspase-dependent apoptosis, and (iv)
counteract ROS production. Indeed, most of these effects have been observed on in vitro and in vivo
PD models, determining neuroprotection and behavioral improvement [228,229] and a randomized
controlled trial has demonstrated NBP efficacy in improving motor symptom and sleep quality of
PD patients [230]. Further studies on cellular models of AD have confirmed neuroprotection and
this positive outcome has been translated also in vivo determining cognitive enhancement [228];
furthermore, increased lifespan and motor performances amelioration have been observed even in
ALS mice thanks to a mitigation of motor neuron loss [228].
Finally, several preclinical trials have been performed on ursodeoxycholic acid and
tauroursodeoxycholic, two drugs currently approved for the treatment of primary biliary sclerosis [231].
As described by Ackerman and Gerhard [232], although their application in neurodegenerative
diseases has to be further investigated, these molecules can (i) exert an antioxidant activity, (ii)
stabilize mitochondrial membrane potential, and (iii) downregulate apoptotic markers. Indeed, in vitro
they have confirmed their role in apoptosis inhibition and membrane stabilization and in vivo
studies have shown behavioral improvement in AD, PD, HD, and ALS models [157,233–235].
Nevertheless, at present, positive outcomes in clinical trials have been obtained only in ALS subjects
providing a delay in the progression of the pathology (NCT00877604 [236,237]).
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Table 5. Compounds targeting simultaneously different mitochondrial dysfunctions. The table lists the molecules that have been tested in preclinical studies or in
clinical trials and that regulate several mitochondrial processes impaired in neurodegenerative diseases. For clinical trial ID we referred to https://clinicaltrials.gov.
Therapeutic Function Drug / Molecule Pathology Preclinical Studies /PMCID Preclinical Results
Clinical Trials / Trial
ID Clinical Results
Antioxidant, mitochondrial
dynamics, permeability and
bioenergetics, MMP
stabilization, and apoptosis
inhibition
3-N-butylphthalide AD
Preclinical in vitro
and in vivo PMID:
30103000 [228]
In vitro: neuroprotection
(apoptosis reduction and
neuronal proliferation)
In vivo: cognitive
impairment amelioration
(synaptic protection,
apoptosis inhibition,
and antioxidant activity)
3-N-butylphthalide ALS Preclinical in vivoPMID: 30103000 [228]
Lifetime extension and motor
performances improvement
(motor neuron loss reduction)
3-N-butylphthalide PD
Preclinical in vitro
and in vivo PMID:
30103000 [228] PMID:
21524431 [229]
Neuroprotection (oxidative
stress mitigation, MMP
stabilization, and mPTP
opening prevention)
Randomized
controlled trial
information is
collected in the
following work
PMC6447885 [230]
(ChiCTR1800018892)
Motor and sleep
quality improvement
Antioxidant, mitochondrial
biogenesis, bioenergetics,
permeability, and dynamics
Curcumin AD
Preclinical in vitro
and in vivo
PMC6716473 [139]
Oxidative stress reduction,
mitochondrial biogenesis and
bioenergetics enhancement,
and MMP stabilization
Curcumin ALS Preclinical in vitroPMC7016185 [151]
Cytotoxicity reduction
(antioxidant activity)
Clinical trials
information is
collected in the
following work
PMC7016185 [151]
Lifespan prolongation
and delaying diseases
progression but
further studies on
different delivery
methods are needed
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Table 5. Cont.
Therapeutic Function Drug / Molecule Pathology Preclinical Studies /PMCID Preclinical Results
Clinical Trials / Trial
ID Clinical Results
Antioxidant, mitochondrial
bioenergetics, and MMP
stabilization
Epigallocatechin-
Gallate
AD
Preclinical in vitro
and in vivo
PMC6716473 [139]
In vitro: antioxidant activity
and MMP restoration
In vivo: improvement of
cognitive functions in rats
injected with streptozotocin
Antioxidant and apoptosis
inhibition
Epigallocatechin-
Gallate
ALS
Preclinical in vitr,
and in vivo
PMC7016185 [151]
In vitro: oxidative stress and
lipid peroxidation reduction;
apoptosis inhibition
In vivo: motor performances
enhancement (increase of
survival signal and reduction
of death signal)
Antioxidant, mitochondrial
bioenergetics, MMP
stabilization, and apoptosis
inhibition
Flavonoids ALS
Preclinical in vitro
in vivo PMC7016185
[151]
In vitro: antioxidant activity
In vivo: motor performances
improvement (prevention of
MN loss)
Antioxidant and apoptosis
inhibition
N-Methyl,N-propynyl-
2-phenylethylamine PD
Preclinical studies
in vivo PMID:
26563498 [226]
MPPE in MPTP-treated mice:
neuroprotection (increase of
Complex I activity and
UCP-2 expression and
antiapoptotic activity) and
motor function enhancement
Antioxidant, mitochondrial
dynamics and bioenergetics,
MMP stabilization,
and apoptosis inhibition
Quercetin AD
Preclinical in vitro
and in vivo
PMC6716473 [139]
In vitro: oxidative stress
reduction and apoptosis
inhibition
In vivo: cognitive functions
improvement; antioxidant
activity, MMP and
mitochondrial morphology
restoration, ROS reduction,
ATP levels increase,
and apoptosis inhibition
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Table 5. Cont.
Therapeutic Function Drug / Molecule Pathology Preclinical Studies /PMCID Preclinical Results
Clinical Trials / Trial
ID Clinical Results
Antioxidant and
mitochondrial permeability
R(+) and S(-)
Pramipexole PD
Preclinical studies
in vitro and in vivo
PMID: 9648878 [224]
PMID: 16407457 [225]
Neuroprotection (reduction
of ROS generation and mPTP
opening prevention)
Antioxidant, mitochondrial
biogenesis and bioenergetics,
MMP stabilization,
and apoptosis inhibition
Resveratrol AD
Preclinical in vitro,
and in vivo
PMC6716473 [139]
In vitro: antioxidant activity,
MMP restoration, apoptosis
inhibition and mitophagy
stimulation
Clinical trial phase
Completed
PMC5234138 [121]
NCT0150485
Cognitive decline
mitigation
In vivo: memory loss
prevention
Antioxidant, mitochondrial
biogenesis and bioenergetics,
MMP stabilization,
and apoptosis inhibition
Resveratrol with
Glucose and Malate AD Not found
Clinical trial phase
3Completed
PMC6240843 [222]
NCT0067843
Safety and tolerability
of low doses are
confirmed
Antioxidant, mitochondrial
biogenesis and bioenergetics,
MMP stabilization,
and apoptosis inhibition
Resveratrol ALS Preclinical in vivoPMC3996124 [220]
Resveratrol in SOD1G93A
ALS mice: delay in pathology
onset and progression and
lower and upper MNs
preservation; increase of
mitochondria biogenesis and
regulation of autophagic flux
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Table 5. Cont.
Therapeutic Function Drug / Molecule Pathology Preclinical Studies /PMCID Preclinical Results
Clinical Trials / Trial
ID Clinical Results
Antioxidant, mitochondrial
dynamics, MMP stabilization,
and apoptosis inhibition
Tauroursodeoxycholic
acid ALS
Preclinical in vitro
PMID: 24848512 [234]
Glycine-conjugated UDCA
exerts an antiapoptotic
activity on NSC34 cells
carrying G93A mutation
Clinical trial Phase
2 Completed
PMC5024041 [236]
NCT0087760
Safety and disease
progression decline
Ursodeoxycholic acid ALS Preclinical in vitroPMID: 24848512 [234]
Already described for
TUDCA
Randomized,
non-controlled trial,
PMC6817734 [237]
Safety and tolerability
are confirmed
Ursodeoxycholic acid ALS Preclinical in vitroPMID: 24848512 [234]
Already described for
TUDCA
Clinical trial Phase 3,
PMC6817734 [237]
ALS progression
decline
Ursodeoxycholic acid AD
Preclinical studies
in vitro PMC6193139
[235]
UDCA on fibroblasts from
AD patients: MMP
restoration involving Drp1
Tauroursodeoxycholic
acid HD
Preclinical in vivo
PMC125009 [233]
Motor and sensory
improvement on R6/2 mice
(neuroprotection)
Ursodeoxycholic acid PD
Preclinical in vitro
and in vivo PMID:
30219247 [157]
Apoptosis inhibition; motor
performances enhancement
(low striatal dopamine
decline)
MMP stabilization and
apoptosis inhibition
Wogonin AD
Preclinical in vitro
and in vivo
PMC5478820 [219]
Wogonin on Tet-On
Aβ42-GFP SH-SY5Y
neuroblastoma cells: MMP
stabilization and apoptosis
inhibition
Wogonin on 3xTg mice:
cognitive functions
improvement
(neuroprotective and
neurotrophic activity)
EGCG = Epigallocatechin-Gallate; MPPE = N-Methyl,N-propynyl-2-phenylethylamine; NBP = 3-N-butylphthalide; Tg = transgenic; UDCA = ursodeoxycholic acid.
Int. J. Mol. Sci. 2020, 21, 3719 23 of 35
5. Conclusions
Besides the recent development of therapies for SMA [238], which still need to be followed for the
long-term response, there is no cure for the neurodegenerative diseases that we described in the review.
Decades after the discovery of the main pathways and genes involved in the pathophysiological
mechanisms of many neurodegenerative processes, researchers and pharmaceutical companies are
still investigating a treatment to cure AD, PD, HD, and ALS. We believe that the key for finding
new effective targets should be to focus on earlier-phenomena occurring, possibly, before evident
degeneration and which could be directed not only to the CNS but also to the PNS and peripheral
tissues. Mitochondrial alterations are one of these early and diffuse events. Indeed, mitochondrial
dysfunctions appear precociously in neurodegeneration and their accumulation trigger or aggravate
the degenerative cascade affecting neuronal tissue, MNs, blood cells, fibroblasts, NMJs, and skeletal
muscles. Moreover, mitochondrial dysfunctions represent a common feature in neurodegeneration
and should be approached as the crosstalk between AD, PD, HD, ALS, and SMA.
Recent therapeutic strategies ranging from natural or synthetic compounds to stem cell therapy,
are targeting mitochondrial pathways which are dysfunctional in the early phases of neurodegeneration.
As we described above, many of them seem promising.
Looking forward, we expect that some of these targets of mitochondrial-directed therapies could
become also biomarkers of neurodegeneration. On the one hand they could be useful to monitor the
progression of the disease, on the other hand they could be an effective read-out to test treatment
efficacy. The greatest advantage for both the daily practice of clinicians and for the health systems
would be the possibility to validate a diagnosis with a non-invasive and cheap method instead of a
time, money, and energy consuming long battery of tests. Moreover, the possibility to develop simple
and non-invasive tests i.e., from patients’ fluids, would be much more helpful for the amelioration of
patients’ motivation and compliance.
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Abbreviations
Aco2 Aconitase 2
CAT Catalase
Cyt C Cytochrome C
DAMPs Damage-associated molecular patterns
DDW Deuterium depleted water
ETC Electron transport chain
Fis1 Mitochondrial fission 1
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GPX Glutathione peroxidase
NLRP3 NOD-, LRR- and pyrin domain-containing protein 3pyrin domain-containing 3
NOX NADPH oxidase
Nrf1 Nuclear respiratory factor 1
OPA1 Protein optic atrophy 1
PBMCs Peripheral blood mononuclear cells
PGK1 Phosphoglycerate kinase 1
PINK1 PTEN-induced kinase 1
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SIRT1 Sirtuin1
SNpc Substantia nigra pars compacta
TCA Tricarboxylic acid
TDP43 TAR DNA-binding protein 43
TFAM Mitochondrial transcription factor A
TPP+ Alkyl-triphenylphosphonium
TSPO Translocator protein
UCP-2 Mitochondrial uncoupling protein 2
VDAC Voltage-dependent ion channel
XO Xanthine oxidase
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